CA3178649A1 - Dosing and administration of activatable anti-ctla-4 antibody - Google Patents

Dosing and administration of activatable anti-ctla-4 antibody

Info

Publication number
CA3178649A1
CA3178649A1 CA3178649A CA3178649A CA3178649A1 CA 3178649 A1 CA3178649 A1 CA 3178649A1 CA 3178649 A CA3178649 A CA 3178649A CA 3178649 A CA3178649 A CA 3178649A CA 3178649 A1 CA3178649 A1 CA 3178649A1
Authority
CA
Canada
Prior art keywords
ctla
antibody
activatable
administered
activatable anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3178649A
Other languages
English (en)
French (fr)
Inventor
Leonard P. JAMES
Michelle Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3178649A1 publication Critical patent/CA3178649A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA3178649A 2020-05-12 2021-05-11 Dosing and administration of activatable anti-ctla-4 antibody Pending CA3178649A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023850P 2020-05-12 2020-05-12
US63/023,850 2020-05-12
PCT/US2021/031670 WO2021231346A1 (en) 2020-05-12 2021-05-11 Dosing and administration of activatable anti-ctla-4 antibody

Publications (1)

Publication Number Publication Date
CA3178649A1 true CA3178649A1 (en) 2021-11-18

Family

ID=76197648

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3178649A Pending CA3178649A1 (en) 2020-05-12 2021-05-11 Dosing and administration of activatable anti-ctla-4 antibody

Country Status (13)

Country Link
US (1) US20230192856A1 (https=)
EP (1) EP4149544A1 (https=)
JP (1) JP2023526232A (https=)
KR (1) KR20230009432A (https=)
CN (1) CN115515633A (https=)
AR (1) AR122043A1 (https=)
AU (1) AU2021270513A1 (https=)
BR (1) BR112022022713A2 (https=)
CA (1) CA3178649A1 (https=)
IL (1) IL298126A (https=)
MX (1) MX2022014113A (https=)
TW (1) TW202207982A (https=)
WO (1) WO2021231346A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260048119A1 (en) * 2022-08-05 2026-02-19 Bristol-Myers Squibb Company Anti-ctla4 antibodies for treatment of kras mutant cancers

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509274A (pt) * 2004-03-26 2007-09-04 Pfizer Prod Inc usos de anticorpos anti-ctla-4
JP2011509299A (ja) * 2008-01-08 2011-03-24 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010042433A1 (en) * 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
HK1203971A1 (en) * 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP2912063A1 (en) * 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
EP3508215A3 (en) * 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
JP6595458B2 (ja) * 2013-09-20 2019-10-23 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
KR20240144452A (ko) * 2014-03-05 2024-10-02 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
WO2015176033A1 (en) * 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US20180133313A1 (en) * 2014-12-16 2018-05-17 Bristol-Myers Squibb Company Use of immune checkpoint inhibitors in central nervous systems neoplasms
US10983128B2 (en) * 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
US10196445B1 (en) * 2015-03-17 2019-02-05 Bristol-Myers Squibb Company Ipilimumab variant with enhanced ADCC
KR20250004095A (ko) * 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
JP2018514550A (ja) * 2015-04-28 2018-06-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
WO2016196389A1 (en) * 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
SMT202500282T1 (it) * 2015-11-18 2025-09-12 Bristol Myers Squibb Co Trattamento del cancro del polmone utilizzando una combinazione di un anticorpo anti-pd-1 e di un anticorpo anti-ctla-4
US20210206854A1 (en) * 2016-01-27 2021-07-08 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
JP2019517512A (ja) * 2016-06-03 2019-06-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用
CN109475634A (zh) * 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
JP7258747B2 (ja) * 2016-10-28 2023-04-17 ブリストル－マイヤーズ スクイブ カンパニー 抗ｐｄ－１抗体を用いた尿路上皮癌の処置方法
MY200695A (en) * 2016-11-03 2024-01-11 Bristol Myers Squibb Co Activatable anti-ctla-4 antibodies and uses thereof
DK3551660T5 (da) * 2016-12-07 2024-09-02 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
JP2020531430A (ja) * 2017-08-16 2020-11-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗体を標的とする抗ｃｔｌａ４プロボディ療法
CN111247169A (zh) * 2017-10-15 2020-06-05 百时美施贵宝公司 治疗肿瘤的方法
CA3084370A1 (en) * 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
US11554120B2 (en) * 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2020086724A1 (en) * 2018-10-23 2020-04-30 Bristol-Myers Squibb Company Methods of treating tumor
CN113316590B (zh) * 2018-11-16 2025-02-28 百时美施贵宝公司 抗nkg2a抗体及其用途
KR20210146348A (ko) * 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020198676A1 (en) * 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
CN113924118A (zh) * 2019-04-18 2022-01-11 百时美施贵宝公司 在低ph下具有增强的结合特异性的伊匹单抗变体
WO2021055994A1 (en) * 2019-09-22 2021-03-25 Bristol-Myers Squibb Company Quantitative spatial profiling for lag-3 antagonist therapy
IL294085A (en) * 2019-12-19 2022-08-01 Bristol Myers Squibb Co Combinations of dgk inhibitors and checkpoint antagonists
KR20220132601A (ko) * 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
EP4097104A1 (en) * 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
WO2023164638A1 (en) * 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2025145207A1 (en) * 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Also Published As

Publication number Publication date
KR20230009432A (ko) 2023-01-17
WO2021231346A1 (en) 2021-11-18
CN115515633A (zh) 2022-12-23
BR112022022713A2 (pt) 2023-03-28
US20230192856A1 (en) 2023-06-22
AU2021270513A1 (en) 2023-01-19
JP2023526232A (ja) 2023-06-21
IL298126A (en) 2023-01-01
EP4149544A1 (en) 2023-03-22
MX2022014113A (es) 2022-12-08
TW202207982A (zh) 2022-03-01
AR122043A1 (es) 2022-08-03

Similar Documents

Publication Publication Date Title
JP7472183B2 (ja) 活性化可能な抗ｃｔｌａ－４抗体およびその使用
RU2733315C2 (ru) Комбинированная терапия для лечения злокачественной опухоли
US10196445B1 (en) Ipilimumab variant with enhanced ADCC
IL259988B (en) Chimeric and humanized monoclonal antibodies against ctla-4 and uses thereof
US12110337B2 (en) Anti-CD27 antibodies and uses thereof
TWI884911B (zh) 具有改良之免疫療效但減弱之副作用之突變抗ctla-4抗體
KR20180102628A (ko) 면역조절제의 조합물에 의한 암의 치료
CN106794246A (zh) 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
US20210395392A1 (en) Anti-mertk antibodies for treating cancer
EP4001308A1 (en) Anti-tigit antibodies and application thereof
WO2020007368A1 (zh) 低adcc/cdc功能性单抗及其制备方法与应用
JP2023554422A (ja) がんの治療のための多重特異性抗体
CA3178649A1 (en) Dosing and administration of activatable anti-ctla-4 antibody
US20240218067A1 (en) Anti-siglec compositions and uses thereof
WO2024240247A1 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 antibodies
US20240002513A1 (en) Dosing and administration of non-fucosylated anti-ctla-4 antibody as monotherapy
TW202613173A (zh) 多特異性抗cd40/抗fap抗體及其用途
EA049996B1 (ru) Антитело к siglec-10 (варианты)

Legal Events

Date Code Title Description
U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20241113

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20251113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251230

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204